Sun Pharma Stocks Crack On Goldman Sach's Downgrade
  • WebDesk BTVI
  • Jun 11 2019

Goldman Sachs has downgraded Sun Pharma to Sell from Neutral rating for target at Rs 355. GS believes that the spending involved will impact profit growth and key profit drivers like India, Taro and US Generics will witness softer growth. Here is Bhasker Pandey with more on the story.